Pulmonary squamous cell carcinoma and sorafenib

Clinical Case Reports

Russell Gollard¹  Diana Garcia² 

[1] Cancer & Blood Specialists of Nevada, Henderson, Nevada;Quest Diagnostics, Las Vegas, Nevada

关键词: BRAF mutants;    nonsmall cell lung cancer;    squamous cell carcinoma;    targeted therapy;   

DOI  :  10.1002/ccr3.95

来源: Wiley

【 摘 要 】

Key Clinical Message

Pulmonary squamous cell carcinomas are not often thought to sensitive to targeted agents, like their cousin the adenocarcinoma of the lung. With appropriate testing of molecular markers, squamous cell carcinomas, like adenocarcinomas of the lung, melanomas, and renal cell carcinomas, may be found to be sensitive to newer, targeted agents.

【 授权许可】

CC BY-NC-ND   
© 2014 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.